UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
January 4, 2022
(Commission File No. 001-40505)
Ambrx Biopharma Inc.
(Translation of registrants name into English)
Cayman Islands
(Jurisdiction of incorporation or organization)
10975 Torrey Pines Road
La Jolla, California 92037
(Address of registrants principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On December 31, 2021, Simon Allen, our Chief Business Officer, informed us of his intent to resign effective January 31, 2022, to pursue another employment opportunity.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
Ambrx Biopharma Inc. | ||
By: |
/s/ Feng Tian |
|
Name: | Feng Tian, Ph.D. | |
Title: | Chief Executive Officer |
Date: January 4, 2022